Clinical Trails

A Phase 1b study evaluated the immunotherapy simlukafusp alfa in patients with metastatic renal cell carcinoma. The drug was tested in combination with atezolizumab, with or without bevacizumab. While the treatment showed biological activity, it did not improve outcomes compared to current standard therapies. The triplet combination showed higher response rates than the doublet. The […]

Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, added to standard FOLFIRI and bevacizumab may significantly improve outcomes in RAS-mutant, microsatellite-stable metastatic colorectal cancer. The combination performed much better than historical results for second-line treatment. Median duration of response reached 19.5 months compared with about 4 to

The Phase 2 CAR-PRISM trial shows striking results for high-risk smoldering multiple myeloma using the CAR T-cell therapy ciltacabtagene autoleucel (Carvykti). A single infusion led to 100% of patients achieving minimal residual disease (MRD) negativity at a very deep level. At a median follow-up of 15.3 months, all patients achieved complete or stringent complete responses, with

Early clinical data suggest that ozekibart (INBRX-109), a DR5 agonist, could offer a new treatment option for Ewing sarcoma, a rare and aggressive cancer. In a Phase 1 study, ozekibart was combined with standard chemotherapy (temozolomide and irinotecan) in patients with relapsed or refractory disease. Among 31 patients, the response rate reached 64.5%, much higher

The Phase 2 PRIMO trial found that duvelisib (Copiktra), an oral drug targeting PI3K-δ and PI3K-γ, can work as a single treatment for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In the study of 123 heavily pretreated patients, nearly half responded to the drug. The overall response rate was 48%, with about one-third

Early results from a Phase 1/2 clinical trial suggest that ozekibart (INBRX-109), a targeted antibody, may offer a new option for patients with advanced colorectal cancer who have already received multiple treatments. When combined with standard chemotherapy (FOLFIRI), the drug showed stronger activity than typically seen in late-stage settings. Among 45 patients, about 20% experienced

Early trial results from the AURORAS-1 and JYP0015M101 studies show that ERAS-0015, a new pan-RAS “molecular glue,” may be highly effective in treating solid tumors with KRAS G12X mutations, including lung and pancreatic cancers. In patients with non-small cell lung cancer, the drug achieved response rates of 62% in those receiving second-line or later treatment,

The COMPANION-002 trial tested Tovecimig (CTX-009) combined with paclitaxel in patients with advanced biliary tract cancer who had already received prior treatment. The combination worked better than paclitaxel alone, nearly doubling progression-free survival to 4.7 months compared with 2.6 months. Tumor response rates were also higher, with 17.1% of patients responding versus 5.3% in the

New early-stage trial results suggest that daraxonrasib (RMC-6236), a new targeted drug, may improve outcomes for patients with metastatic pancreatic cancer who have not yet received treatment. In two Phase 1/2 studies, daraxonrasib showed strong anti-tumor activity both alone and when combined with chemotherapy. Response rates reached 47% with the drug alone and 58% when

Results from the CAR-PRISM phase 2 trial show that the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) produced remarkable outcomes in patients with high-risk smoldering multiple myeloma, a precursor to active cancer. All 20 patients in the study responded to treatment, with most achieving deep remissions. Every patient became minimal residual disease (MRD) negative within two